Legacy

Researh Projects

Relevant outcomes for patients and caregivers are defined for each blood cancer, defined by the HARMONY Research Teams. HARMONY Research Projects are focusing on those particular outcomes that will expand our knowledge of Hematologic Malignancies and therapeutic approaches. 

ALL-4: Harnessing the Power of Big Data to Predict Outcomes Post-Stem Cell Transplant in Adult R/R ALL

NHL: Using big data to optimize outcomes in T-cell Non-Hodgkin Lymphomas

MPN-1: Exploring the Impact of Covid-19 on Outcomes in Myeloproliferative Neoplasms

AML-4: Using big data to confirm the link between MRD and survival in AML

AML-5: Exploring a role for HARMONY data as historical control in elderly Acute Myeloid Leukemia patients.

MDS-1: Prognostic factors to hypomethylating agents and intensive chemotherapy in higher risk Myelodysplastic Syndromes

AML-1: Use of Big Data to revise treatment strategies in Acute Myeloid Leukemia

CLL-2: Exploring the occurrence of other malignancies in CLL patients using the HARMONY BigData platform

CML-3: A comparison study of “toxicity over time” and QoL among all available TKI options

AML-8: Clinical Meaning and Prognostic Implications of Non-Canonical Non-Type A NPM1 Mutations in Acute Myeloid Leukemia

AML-2: Optimizing Acute Promyelocytic Leukemia Management Using Big Data

AML-3: Using big data to shed light on the clinical impact of genomic alterations in sAML/tAML

MDS-4 Impact of pre-transplant cytoreductive treatment on high-risk MDS patients undergoing allo-HSCT

CML-5: Prevalence of clinically relevant problems and symptoms in patients with CML

CML-4: Correlation of demographic, disease and therapy factors with toxicity and tolerability of the different TKIs

CML-1: Understanding the clonal hierarchy in Chronic Myeloid Leukemia to help improve patient outcomes

CML-2: Using Big Data to Map and Identify Optimal Treatment Pathways to Treatment-Free Remission in CML

MDS-3: Differential outcomes of patients with MDS undergoing HSCT vs non-transplant strategies

CLL-1: Harnessing big data to predict prognosis in Chronic Lymphocytic Leukemia

ALL-5: Exploring the prognostic significance of minimal residual disease (MRD) in children with ALL

MM-2: Contextualizing clinical trials by developing robust historical control arm cohort

ALL-3: Exploring treatment patterns and outcomes in older adult B-ALL

MM-1: Optimizing prognostication and personalizing treatment in Multiple Myeloma

AML-6: Unravelling the Clinical Impact of Co-mutations in NPM1mut AML

MDS-2: A retrospective study of patients with Myelodysplastic Syndrome

AML-7: The impact of gender on genetic aberrations and clinical outcomes in AML

AML-7: The impact of gender on genetic aberrations and clinical outcomes in AML

ALL 1: Use of Big Data to improve outcomes for patients with Acute Lymphoblastic Leukemia

Spain

  • PETHEMA – Programa Español de Tratamientos en Hematología
  • Jose Carreras Leukemia Research Institute
  • Spanish CETLAM Cooperative Group
  • Hospital 12 de Octubre – i+12 Instituto de Investigación
  • Hospital Universitario La Fe
  • Fundació Institut Mar D´Investigacions Mèdiques
  • Complejo Asistencial Universitario de Burgos
  • Ramon y Cajal University Hospital
  • Infanta Leonor Hospital
  • Costa del Sol Hospital
  • Hospital General Universitario Valencia
  • Catalan Registry of CML
  • Hospital Universitario de Gran Canaria Doctor Negrín
  • GESMD – Grupo Español de Síndromes Mielodisplásicos
  • FICUS – Fundación de Investigación del Cáncer de la Universidad de Salamanca / CIC Salamanca
  • Registro Gammapatías Castilla y León